Oral Contraceptive Use and Breast Cancer Risk: Retrospective and Prospective Analyses From a BRCA1 and BRCA2 Mutation Carrier Cohort Study - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue JNCI Cancer Spectrum Année : 2021

Oral Contraceptive Use and Breast Cancer Risk: Retrospective and Prospective Analyses From a BRCA1 and BRCA2 Mutation Carrier Cohort Study

(1) , (2) , (3, 4) , (5) , (6) , (7) , (8, 9) , (1) , (10) , (11) , (12) , (13) , (11) , (14) , (11) , (15) , (16) , (17) , (18) , (19) , (20) , (21, 22) , (23) , (24) , (25) , (26) , (27, 28) , (29) , (30) , (31, 32) , (33) , (34) , (35) , (36) , (1) , (37, 38) , (4, 39) , (40) , (40) , (41) , (41, 42) , (43) , (44) , (45) , (46) , (47) , (32) , (48) , (49) , (50) , (11) , (1) , (4) , (4, 51) , (11) , (1)
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
Daniel Barrowdale
Jacques Simard
Matti A Rookus
  • Fonction : Auteur
  • PersonId : 882439

Résumé

Background: For BRCA1 and BRCA2 mutation carriers, the association between oral contraceptive preparation (OCP) use and breast cancer (BC) risk is still unclear. Methods: Breast camcer risk associations were estimated from OCP data on 6030 BRCA1 and 3809 BRCA2 mutation carriers using age-dependent Cox regression, stratified by study and birth cohort. Prospective, left-truncated retrospective and full-cohort retrospective analyses were performed. Results: For BRCA1 mutation carriers, OCP use was not associated with BC risk in prospective analyses (hazard ratio [HR] = 1.08, 95% confidence interval [CI] = 0.75 to 1.56), but in the left-truncated and full-cohort retrospective analyses, risks were increased by 26% (95% CI = 6% to 51%) and 39% (95% CI = 23% to 58%), respectively. For BRCA2 mutation carriers, OCP use was associated with BC risk in prospective analyses (HR = 1.75, 95% CI = 1.03 to 2.97), but retrospective analyses were inconsistent (left-truncated: HR = 1.06, 95% CI = 0.85 to 1.33; full cohort: HR = 1.52, 95% CI = 1.28 to 1.81). There was evidence of increasing risk with duration of use, especially before the first full-term pregnancy (BRCA1: both retrospective analyses, P < .001 and P = .001, respectively; BRCA2: full retrospective analysis, P = .002). Conclusions: Prospective analyses did not show that past use of OCP is associated with an increased BC risk for BRCA1 mutation carriers in young middle-aged women (40-50 years). For BRCA2 mutation carriers, a causal association is also not likely at those ages. Findings between retrospective and prospective analyses were inconsistent and could be due to survival bias or a true association for younger women who were underrepresented in the prospective cohort. Given the uncertain safety of long-term OCP use for BRCA1/2 mutation carriers, indications other than contraception should be avoided and nonhormonal contraceptive methods should be discussed.
Fichier principal
Vignette du fichier
pky023.pdf (737.79 Ko) Télécharger le fichier
Origine : Publication financée par une institution

Dates et versions

inserm-03342591 , version 1 (13-09-2021)

Identifiants

Citer

Lieske H Schrijver, Håkan Olsson, Kelly-Anne Phillips, Mary Beth Terry, David E Goldgar, et al.. Oral Contraceptive Use and Breast Cancer Risk: Retrospective and Prospective Analyses From a BRCA1 and BRCA2 Mutation Carrier Cohort Study. JNCI Cancer Spectrum, 2021, 2 (2), pky023. ⟨10.1093/jncics/pky023⟩. ⟨inserm-03342591⟩
25 Consultations
24 Téléchargements

Altmetric

Partager

Gmail Facebook Twitter LinkedIn More